Positive allosteric modulators (PAMs) of muscarinic acetylcholine M1 receptor are being developed to address cognitive deficits in Alzheimer’s disease, schizophrenia and other neuropsychiatric ...

New therapeutic strategies against P. aeruginosa are urgently needed. Polyclonal antibodies (pAbs) may provide broader coverage than mAbs by recognizing multiple bacterial epitopes and reducing immune ...

Parkinson’s disease (PD) is driven not only by dopamine loss but also by neurodegenerative processes linked to iron dysregulation and ferroptosis in the substantia nigra. Researchers from Zhejiang ...

A gene therapy for treating X-linked retinitis pigmentosa is edging closer to approval, with Beacon Therapeutics Ltd. reporting positive results from the pivotal phase II/III trial of laruparetigene ...

NACHT, LRR and PYD domains-containing protein 3 (NLRP3) is a sensor of cellular damage and stress in immune cells, thus being an interesting target for inflammatory diseases, such as Alzheimer’s (AD) ...

Maze Therapeutics Inc. has synthesized sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors potentially useful for the treatment of phenylketonuria, metabolic syndrome and ...

Total biopharma financings through August 2026 reached $77.13 billion for the year, closely matching 2024's $77.52 billion ...

A new study, which for the first time attempts to model the global impact of U.S. President Donald Trump’s most-favored nation (MFN) drug pricing, reinforces emerging real-world evidence that the ...

As Amgen Inc.’s Imdelltra (tarlatamab) pushes into the first-line setting for small-cell lung cancer, a fast-growing field of ...

Even as the treatment potential for GLP-1 drugs continues to expand beyond metabolic indications, recognition grows for the ...

Pricing the first biopharma IPO in the month of September, precision medicine company Electra Therapeutics Inc. is raising $350 million to advance the phase II/III registrational development of novel ...

A egative readout from the phase III study of Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) raised the bar for antibody-drug conjugates (ADCs) seeking to move into the first-line ...